Advertisement

Diabetologia

pp 1–13 | Cite as

Circulating palmitoleic acid is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals: a longitudinal analysis

  • Domenico TricòEmail author
  • Alessandro Mengozzi
  • Lorenzo Nesti
  • Mensud Hatunic
  • Rafael Gabriel Sanchez
  • Thomas Konrad
  • Katarina Lalić
  • Nebojša M. Lalić
  • Andrea Mari
  • Andrea Natali
  • for the EGIR-RISC Study Group
Article

Abstract

Aims/hypothesis

Experimental studies suggest that the fatty acid palmitoleate may act as an adipocyte-derived lipid hormone (or ‘lipokine’) to regulate systemic metabolism. We investigated the relationship of circulating palmitoleate with insulin sensitivity, beta cell function and glucose tolerance in humans.

Methods

Plasma NEFA concentration and composition were determined in non-diabetic individuals from the Relationship between Insulin Sensitivity and Cardiovascular disease (RISC) study cohort at baseline (n = 1234) and after a 3 year follow-up (n = 924). Glucose tolerance, insulin secretion and beta cell function were assessed during an OGTT. Whole-body insulin sensitivity was measured by a hyperinsulinaemic–euglycaemic clamp (M/I) and OGTT (oral glucose insulin sensitivity index [OGIS]). The liver insulin resistance index was calculated using clinical and biochemical data. Body composition including fat mass was determined by bioelectrical impedance.

Results

Circulating palmitoleate was proportional to fat mass (r = 0.21, p < 0.0001) and total NEFA levels (r = 0.19, p < 0.0001). It correlated with whole-body insulin sensitivity (M/I: standardised regression coefficient [std. β] = 0.16, p < 0.0001), liver insulin resistance (std. β = −0.14, p < 0.0001), beta cell function (potentiation: std. β = 0.08, p = 0.045) and glucose tolerance (2 h glucose: std. β = −0.24, p < 0.0001) after adjustment for age, sex, BMI, adiposity and other NEFA. High palmitoleate concentrations prevented the decrease in insulin sensitivity associated with excess palmitate (p = 0.0001). In a longitudinal analysis, a positive independent relationship was observed between changes in palmitoleate and insulin sensitivity over time (std. β = 0.07, p = 0.04).

Conclusions/interpretation

We demonstrated that plasma palmitoleate is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals. These results support the role of palmitoleate as a beneficial lipokine released by adipose tissue to prevent the negative effects of adiposity and excess NEFA on systemic glucose metabolism.

Keywords

Adipokine Beta cell function Glucose tolerance Insulin sensitivity Lipokine Monounsaturated fatty acid NEFA Palmitate Palmitoleic acid Subcutaneous adipose tissue 

Abbreviations

FFM

Fat-free mass

FM%

Percentage fat mass

IFG

Impaired fasting glucose

IGT

Impaired glucose tolerance

MUFA

Monounsaturated fatty acid

NGT

Normal glucose tolerance

OGIS

Oral glucose insulin sensitivity index

PO%

Percentage palmitoleate enrichment in the total NEFA pool

PUFA

Polyunsaturated fatty acid

RISC

Relationship between Insulin Sensitivity and Cardiovascular disease study

SCD-1

Stearoyl-CoA desaturase-1

SFA

Saturated fatty acid

std. β

Standardised regression coefficient

Notes

Acknowledgements

Preliminary study findings were presented as an abstract at the 55th EASD Annual Meeting in Barcelona, Spain, in 2019.

Contribution statement

DT contributed to study design, data analysis and interpretation and writing the manuscript. AMe, LN, MH, RGS, TK, KL and NML contributed to data collection and edited the manuscript. AM undertook the mathematical modelling of insulin secretion and beta cell function variables, contributed to data interpretation and edited the manuscript. AN contributed to study design and supervision, securing of funding, and data collection, analysis and interpretation, and edited and critically revised the manuscript. All authors read and approved the final submitted version of the manuscript. DT and AN are the guarantors of this work and, as such, have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Funding

The RISC study was partly supported by European Union grant QLG1-CT-2001-01252. DT is funded by the European Foundation for the Study of Diabetes (EFSD) Mentorship Programme.

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript.

Supplementary material

125_2019_5013_MOESM1_ESM.pdf (169 kb)
ESM Figures (PDF 168 kb)

References

  1. 1.
    Opie LH, Walfish PG (1963) Plasma free fatty acid concentrations in obesity. N Engl J Med 268:757–760.  https://doi.org/10.1056/NEJM196304042681404 CrossRefPubMedGoogle Scholar
  2. 2.
    Boden G, Shulman GI (2002) Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 32(Suppl 3):14–23CrossRefGoogle Scholar
  3. 3.
    Boden G (2002) Interaction between free fatty acids and glucose metabolism. Curr Opin Clin Nutr Metab Care 5(5):545–549CrossRefGoogle Scholar
  4. 4.
    Johnston LW, Harris SB, Retnakaran R et al (2018) Association of NEFA composition with insulin sensitivity and beta cell function in the Prospective Metabolism and Islet Cell Evaluation (PROMISE) cohort. Diabetologia 61(4):821–830.  https://doi.org/10.1007/s00125-017-4534-6 CrossRefPubMedGoogle Scholar
  5. 5.
    Seghieri M, Trico D, Natali A (2017) The impact of triglycerides on glucose tolerance: Lipotoxicity revisited. Diabetes Metab 43(4):314–322.  https://doi.org/10.1016/j.diabet.2017.04.010 CrossRefPubMedGoogle Scholar
  6. 6.
    Hodson L, Skeaff CM, Fielding BA (2008) Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res 47(5):348–380.  https://doi.org/10.1016/j.plipres.2008.03.003 CrossRefPubMedGoogle Scholar
  7. 7.
    Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS (2008) Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell 134(6):933–944.  https://doi.org/10.1016/j.cell.2008.07.048 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Stefan N, Kantartzis K, Celebi N et al (2010) Circulating palmitoleate strongly and independently predicts insulin sensitivity in humans. Diabetes Care 33(2):405–407.  https://doi.org/10.2337/dc09-0544 CrossRefPubMedGoogle Scholar
  9. 9.
    Pinnick KE, Neville MJ, Fielding BA, Frayn KN, Karpe F, Hodson L (2012) Gluteofemoral adipose tissue plays a major role in production of the lipokine palmitoleate in humans. Diabetes 61(6):1399–1403.  https://doi.org/10.2337/db11-1810 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Bergman BC, Howard D, Schauer IE et al (2013) The importance of palmitoleic acid to adipocyte insulin resistance and whole-body insulin sensitivity in type 1 diabetes. J Clin Endocrinol Metab 98(1):E40–E50.  https://doi.org/10.1210/jc.2012-2892 CrossRefPubMedGoogle Scholar
  11. 11.
    Nunes EA, Rafacho A (2017) Implications of palmitoleic acid (palmitoleate) on glucose homeostasis, insulin resistance and diabetes. Curr Drug Targets 18(6):619–628.  https://doi.org/10.2174/1389450117666151209120345 CrossRefPubMedGoogle Scholar
  12. 12.
    de Souza CO, Vannice GK, Rosa Neto JC, Calder PC (2018) Is palmitoleic acid a plausible nonpharmacological strategy to prevent or control chronic metabolic and inflammatory disorders? Mol Nutr Food Res 62(1).  https://doi.org/10.1002/mnfr.201700504
  13. 13.
    Mozaffarian D, Cao H, King IB et al (2010) Trans-palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a cohort study. Ann Intern Med 153(12):790–799.  https://doi.org/10.7326/0003-4819-153-12-201012210-00005 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Yang ZH, Miyahara H, Hatanaka A (2011) Chronic administration of palmitoleic acid reduces insulin resistance and hepatic lipid accumulation in KK-Ay mice with genetic type 2 diabetes. Lipids Health Dis 10:120.  https://doi.org/10.1186/1476-511X-10-120 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Dimopoulos N, Watson M, Sakamoto K, Hundal HS (2006) Differential effects of palmitate and palmitoleate on insulin action and glucose utilization in rat L6 skeletal muscle cells. Biochem J 399(3):473–481.  https://doi.org/10.1042/BJ20060244 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Matsuzaka T, Shimano H, Yahagi N et al (2007) Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat Med 13(10):1193–1202.  https://doi.org/10.1038/nm1662 CrossRefPubMedGoogle Scholar
  17. 17.
    Bolsoni-Lopes A, Festuccia WT, Chimin P et al (2014) Palmitoleic acid (n-7) increases white adipocytes GLUT4 content and glucose uptake in association with AMPK activation. Lipids Health Dis 13:199.  https://doi.org/10.1186/1476-511X-13-199 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    de Souza CO, Teixeira AAS, Biondo LA, Lima Junior EA, Batatinha HAP, Rosa Neto JC (2017) Palmitoleic acid improves metabolic functions in fatty liver by PPARα-dependent AMPK activation. J Cell Physiol 232(8): 2168-2177.  https://doi.org/10.1002/jcp.25715
  19. 19.
    Maedler K, Oberholzer J, Bucher P, Spinas GA, Donath MY (2003) Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes 52(3):726–733CrossRefGoogle Scholar
  20. 20.
    Vessby B, Tengblad S, Lithell H (1994) Insulin sensitivity is related to the fatty acid composition of serum lipids and skeletal muscle phospholipids in 70-year-old men. Diabetologia 37(10):1044–1050CrossRefGoogle Scholar
  21. 21.
    Kusunoki M, Tsutsumi K, Nakayama M et al (2007) Relationship between serum concentrations of saturated fatty acids and unsaturated fatty acids and the homeostasis model insulin resistance index in Japanese patients with type 2 diabetes mellitus. J Med Invest 54(3-4):243–247CrossRefGoogle Scholar
  22. 22.
    Mozaffarian D, Cao H, King IB et al (2010) Circulating palmitoleic acid and risk of metabolic abnormalities and new-onset diabetes. Am J Clin Nutr 92(6):1350–1358.  https://doi.org/10.3945/ajcn.110.003970 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Fabbrini E, Magkos F, Su X et al (2011) Insulin sensitivity is not associated with palmitoleate availability in obese humans. J Lipid Res 52(4):808–812.  https://doi.org/10.1194/jlr.M013599 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Hills SA, Balkau B, Coppack SW et al (2004) The EGIR-RISC Study (The European Group for the study of Insulin Resistance: Relationship between Insulin Sensitivity and Cardiovascular disease risk): I. Methodology and objectives. Diabetologia 47(3):566–570.  https://doi.org/10.1007/s00125-004-1335-5 CrossRefPubMedGoogle Scholar
  25. 25.
    American Diabetes Association (2019) Classification and diagnosis of diabetes: standards of medical care in diabetes–2019. Diabetes Care 42(Suppl 1):S13–S28.  https://doi.org/10.2337/dc19-S002 CrossRefGoogle Scholar
  26. 26.
    Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ (2001) A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 24(3):539–548Google Scholar
  27. 27.
    Vangipurapu J, Stancakova A, Kuulasmaa T et al (2011) A novel surrogate index for hepatic insulin resistance. Diabetologia 54(3):540–543.  https://doi.org/10.1007/s00125-010-1966-7 CrossRefPubMedGoogle Scholar
  28. 28.
    Van Cauter E, Mestrez F, Sturis J, Polonsky KS (1992) Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41(3):368–377CrossRefGoogle Scholar
  29. 29.
    Mari A, Ferrannini E (2008) Beta-cell function assessment from modelling of oral tests: an effective approach. Diabetes Obesity Meta 10(Suppl 4):77–87.  https://doi.org/10.1111/j.1463-1326.2008.00946.x
  30. 30.
    Mari A, Tura A, Natali A et al (2010) Impaired beta cell glucose sensitivity rather than inadequate compensation for insulin resistance is the dominant defect in glucose intolerance. Diabetologia 53(4):749–756CrossRefGoogle Scholar
  31. 31.
    Trico D, Filice E, Baldi S, Frascerra S, Mari A, Natali A (2016) Sustained effects of a protein and lipid preload on glucose tolerance in type 2 diabetes patients. Diabetes Metab 42(4):242–248.  https://doi.org/10.1016/j.diabet.2016.03.004 CrossRefPubMedGoogle Scholar
  32. 32.
    Gall WE, Beebe K, Lawton KA et al (2010) Alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One 5(5):e10883.  https://doi.org/10.1371/journal.pone.0010883
  33. 33.
    Carta G, Murru E, Banni S, Manca C (2017) Palmitic acid: physiological role, metabolism and nutritional implications. Front Physiol 8:902.  https://doi.org/10.3389/fphys.2017.00902
  34. 34.
    Maeda K, Cao H, Kono K et al (2005) Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 1(2):107–119.  https://doi.org/10.1016/j.cmet.2004.12.008 CrossRefPubMedGoogle Scholar
  35. 35.
    Gravena C, Mathias PC, Ashcroft SJ (2002) Acute effects of fatty acids on insulin secretion from rat and human islets of Langerhans. J Endocrinol 173(1):73–80CrossRefGoogle Scholar
  36. 36.
    Palomer X, Pizarro-Delgado J, Barroso E, Vazquez-Carrera M (2018) Palmitic and oleic acid: the yin and yang of fatty acids in type 2 diabetes mellitus. Trends Endocrinol Metab 29(3):178–190.  https://doi.org/10.1016/j.tem.2017.11.009 CrossRefPubMedGoogle Scholar
  37. 37.
    Walker CG, Browning LM, Stecher L et al (2015) Fatty acid profile of plasma NEFA does not reflect adipose tissue fatty acid profile. Br J Nutr 114(5):756–762.  https://doi.org/10.1017/S0007114515002251 CrossRefPubMedGoogle Scholar
  38. 38.
    Knutsen SF, Fraser GE, Beeson WL, Lindsted KD, Shavlik DJ (2003) Comparison of adipose tissue fatty acids with dietary fatty acids as measured by 24-hour recall and food frequency questionnaire in Black and White Adventists: the Adventist Health Study. Ann Epidemiol 13(2):119–127CrossRefGoogle Scholar
  39. 39.
    Hodge AM, Simpson JA, Gibson RA et al (2007) Plasma phospholipid fatty acid composition as a biomarker of habitual dietary fat intake in an ethnically diverse cohort. Nutr Metab Cardiovasc Dis 17(6):415–426.  https://doi.org/10.1016/j.numecd.2006.04.005 CrossRefPubMedGoogle Scholar
  40. 40.
    Nestel P, Clifton P, Noakes M (1994) Effects of increasing dietary palmitoleic acid compared with palmitic and oleic acids on plasma lipids of hypercholesterolemic men. J Lipid Res 35(4):656–662PubMedGoogle Scholar
  41. 41.
    Curb JD, Wergowske G, Dobbs JC, Abbott RD, Huang B (2000) Serum lipid effects of a high-monounsaturated fat diet based on macadamia nuts. Arch Intern Med 160(8):1154–1158CrossRefGoogle Scholar
  42. 42.
    Garg ML, Blake RJ, Wills RB (2003) Macadamia nut consumption lowers plasma total and LDL cholesterol levels in hypercholesterolemic men. J Nutr 133(4):1060–1063.  https://doi.org/10.1093/jn/133.4.1060 CrossRefPubMedGoogle Scholar
  43. 43.
    Hiraoka-Yamamoto J, Ikeda K, Negishi H et al (2004) Serum lipid effects of a monounsaturated (palmitoleic) fatty acid-rich diet based on macadamia nuts in healthy, young Japanese women. Clin Exp Pharmacol Physiol 31(Suppl 2):S37–S38.  https://doi.org/10.1111/j.1440-1681.2004.04121.x CrossRefPubMedGoogle Scholar
  44. 44.
    Griel AE, Cao Y, Bagshaw DD, Cifelli AM, Holub B, Kris-Etherton PM (2008) A macadamia nut-rich diet reduces total and LDL-cholesterol in mildly hypercholesterolemic men and women. J Nutr 138(4):761–767.  https://doi.org/10.1093/jn/138.4.761 CrossRefPubMedGoogle Scholar
  45. 45.
    Hodson L, Fielding BA (2013) Stearoyl-CoA desaturase: rogue or innocent bystander? Prog Lipid Res 52(1):15–42.  https://doi.org/10.1016/j.plipres.2012.08.002 CrossRefPubMedGoogle Scholar
  46. 46.
    Canoy D, Luben R, Welch A et al (2004) Fat distribution, body mass index and blood pressure in 22,090 men and women in the Norfolk cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk) study. J Hypertens 22(11):2067–2074CrossRefGoogle Scholar
  47. 47.
    Yusuf S, Hawken S, Ounpuu S et al (2005) Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 366(9497):1640–1649.  https://doi.org/10.1016/S0140-6736(05)67663-5 CrossRefPubMedGoogle Scholar
  48. 48.
    Venturi E, Pinnola S, Morizzo C et al (2016) Clinical phenotype and microvascular dynamics of subjects with endothelial dysfunction as assessed by peripheral tonometry. Microcirculation 23(3):230–239.  https://doi.org/10.1111/micc.12268 CrossRefPubMedGoogle Scholar
  49. 49.
    Umano GR, Shabanova V, Pierpont B et al (2019) A low visceral fat proportion, independent of total body fat mass, protects obese adolescent girls against fatty liver and glucose dysregulation: a longitudinal study. Int J Obes (Lond) 43(4):673–682.  https://doi.org/10.1038/s41366-018-0227-6 CrossRefGoogle Scholar
  50. 50.
    Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G (1997) Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 100(5):1166–1173.  https://doi.org/10.1172/JCI119628 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Domenico Tricò
    • 1
    • 2
    Email author
  • Alessandro Mengozzi
    • 1
  • Lorenzo Nesti
    • 1
  • Mensud Hatunic
    • 3
  • Rafael Gabriel Sanchez
    • 4
  • Thomas Konrad
    • 5
  • Katarina Lalić
    • 6
  • Nebojša M. Lalić
    • 6
  • Andrea Mari
    • 7
  • Andrea Natali
    • 1
  • for the EGIR-RISC Study Group
  1. 1.Department of Clinical and Experimental MedicineUniversity of PisaPisaItaly
  2. 2.Institute of Life SciencesSant’Anna School of Advanced StudiesPisaItaly
  3. 3.Department of EndocrinologyMater Misericordiae University Hospital, University College Dublin School of MedicineDublinIreland
  4. 4.Unidad de InvestigacionHospital Universitario de la PrincesaMadridSpain
  5. 5.Institute for Metabolic ResearchGoethe UniversityFrankfurt am MainGermany
  6. 6.Faculty of MedicineUniversity of BelgradeBelgradeSerbia
  7. 7.Institute of NeuroscienceNational Research CouncilPaduaItaly

Personalised recommendations